Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plus Therapeutics, Inc. (NASDAQ: PSTV) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering investors a structured view of its financial condition, capital structure, governance, and clinical-stage operations. As a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and CNS cancer diagnostics, Plus Therapeutics uses SEC reports to describe its business, risks, and material events.
Core filings such as the Form 10-K annual report and Form 10-Q quarterly reports provide detailed discussions of the company’s radiotherapeutic pipeline, including REYOBIQ™ (rhenium Re186 obisbemeda), its CNSide Diagnostics subsidiary, grant funding, and liquidity. These documents also outline risk factors related to clinical development, regulatory approvals, Nasdaq listing standards, and capital needs.
Frequent Form 8-K current reports disclose material events, including Nasdaq notices about minimum bid price and stockholders’ equity compliance, extensions to regain listing compliance, purchase agreements with institutional investors, public offerings of common stock and warrants, and significant lease or financing arrangements. Proxy materials on Schedule 14A describe board elections, stock incentive plans, reverse stock split authority, and stockholder voting outcomes.
On this page, Stock Titan enhances access to these filings with AI-powered summaries that explain key points in plain language, helping users quickly understand complex documents such as registration statements on Form S-1, equity purchase agreements, or governance-related filings. Real-time integration with the SEC’s EDGAR system ensures new Plus Therapeutics filings appear promptly.
Investors can also use this section to monitor potential insider activity reported on ownership forms, as well as to follow any future proxy statements addressing compensation or capital structure changes. By combining raw filings with AI-generated highlights, the page is designed to make Plus Therapeutics’ regulatory history and ongoing disclosure record more accessible to both experienced and newer market participants.
Plus Therapeutics (PSTV) disclosed a new long-term facility lease in Houston. The company agreed to lease approximately 11,370 rentable square feet at 6420 Levit Green Boulevard, with the lease expected to commence on or about November 1, 2026. The initial term is 120 calendar months.
Monthly base rent starts at $58,745 and increases annually by approximately 3%, plus the company’s share of the building’s direct expenses. This creates a multi-year operating commitment tied to growth and operational needs at the Houston site.
Marc H. Hedrick, who is both Chief Executive Officer and a Director of Plus Therapeutics, Inc. (PSTV), had restricted stock units vest on 10/01/2025. The vesting resulted in the acquisition of 159,681 shares of common stock at $0 cost per share because these were RSU settlements, and the filing reports Mr. Hedrick's direct beneficial ownership following the transaction as 180,106 shares in the non-derivative table and 1,756,487 shares in the derivative/underlying summary.
The Form 4 shows these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025, and that the report was submitted by an attorney-in-fact. This is a standard disclosure of insider equity vesting that increases the reporting person’s share holdings and signals management’s equity position without any cash purchase recorded.
Marc H. Hedrick, identified as Director and Chief Executive Officer of Plus Therapeutics, Inc. (PSTV), reported equity awards dated 08/13/2025 in an amended Form 4/A. The filing shows an award of 5,748,506 stock options with an exercise price of $0.5744 and an award of 1,916,168 Restricted Stock Units (RSUs). The RSUs vest over twelve quarters, beginning with the quarter ended September 30, 2025, and convert one-for-one into common shares on vesting. The amendment corrects previously disclosed vesting terms for the RSUs. The Form 4/A is signed by an attorney-in-fact on behalf of the reporting person on 10/03/2025.
Andrew John Hugh MacIntyre Sims, listed as Chief Financial Officer and Director of Plus Therapeutics, Inc. (PSTV), filed a Form 4 disclosing insider changes effective 10/01/2025. The filing reports the vesting of 38,323 Restricted Stock Units (RSUs) that are each a contingent right to one share, recorded with a transaction code M and a reported price of $0. After the reported transaction the filing shows 48,138 shares of Common Stock beneficially owned directly and 421,555 derivative securities (RSUs) reported as beneficially owned following the transaction. The filing states these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025.
PLUS THERAPEUTICS, INC. (PSTV) disclosure shows an amendment to an insider Form 4 for Andrew Sims, the company's Chief Financial Officer, correcting previously reported vesting terms. On 08/13/2025 Mr. Sims was awarded 1,379,636 stock options with an exercise price of $0.5744 and 459,878 restricted stock units (RSUs). The options vest over four years in equal monthly 1/48th installments and expire 08/12/2035. The amended RSU disclosure clarifies they vest over twelve quarters in substantially equal 1/12th increments beginning with the quarter ended 09/30/2025 and convert one-for-one into common shares upon vesting. The filing is signed by Mr. Sims on 10/03/2025.
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company is back in compliance with two key continued listing standards. Nasdaq determined that Plus Therapeutics meets the Market Value of Listed Securities standard, which requires a market value of at least $35 million, and the stockholders’ equity standard, which requires equity of at least $2.5 million. As a result, the company now satisfies two alternative criteria under Nasdaq Listing Rule 5550.
Because of this, Nasdaq has allowed Plus Therapeutics to use the remainder of its grace period to fix its continued deficiency under the $1.00 bid price rule, extending the deadline to November 12, 2025 instead of the earlier September 8, 2025 date. However, the company’s compliance with the equity requirement is subject to a one-year monitoring period through August 22, 2026. If it falls out of compliance with the equity standard and does not meet another alternative standard during that period, Nasdaq staff would issue a delisting determination, and the company’s only recourse would be to request a new hearing.
PLUS THERAPEUTICS (PSTV) director Robert P. Lenk reported a purchase of 110,000 shares of common stock on 08/22/2025 at a price of $0.4889 per share. After the transaction he beneficially owns 139,327 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and documents a routine insider open-market purchase.
Plus Therapeutics, Inc. submitted a Form S-8 registering employee benefit plans and associated agreements for use with equity awards. The filing lists the Fifth Amended and Restated 2020 Stock Incentive Plan, multiple forms of stock/unit/option agreements, historical employee plans and amendments dating back to
Plus Therapeutics director received option awards totaling 337,794 shares on 08/13/2025. The grants consist of a 297,794-option award and a 40,000-option award, both with an exercise price of $0.5744 per share and an expiration date of 08/12/2035. The larger award vests monthly over 12 months but accelerates to full vesting at the issuer's 2026 annual meeting if the reporting person remains in service; the smaller award vests monthly over 24 months. The filing was reported by an attorney-in-fact and reflects beneficial ownership of 337,794 underlying shares following the transactions.
PLUS THERAPEUTICS, Inc. (PSTV) reported an equity award to Marc H. Hedrick, its Chief Executive Officer and a director. On 08/13/2025 he was granted stock options to purchase 5,748,506 shares with an exercise price of $0.5744 and an expiration date of 08/12/2035, and 1,916,168 restricted stock units that convert one-for-one into common stock upon vesting. The option grant vests monthly over four years in equal 1/48th installments. The RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the following two years.